Rodrigo Dienstmann, MD [7505]
How do you use NGS to detect, classify, and report an actionable alteration from a tumor sample and how should this be reported to a clinician to facilitate alignment between a specific genomic alteration/mutation and a targeted therapy ...
What are the results of the most recent clinical trials evaluating the role of NGS in optimizing clinical outcomes in precision cancer medicine? What is the role of mutant allele fractions and other quantifications? And what is the role ...
The current FoundationOne assay examines about 315 genes known to be somatically altered in human solid tumors, as well as 28 translocations. How were these genes determined? What makes them significant? (English)
When FoundationOne NGS is applied to such common cancers as lung, breast, and colorectal, what is the failure rate? What percentage of samples will have at least one actionable alteration? What is the frequency of actionable mutations ...
Can targeted therapies based on NGS-based genomic alterations still be employed even after a patient has failed a first-line therapy? Are targeted, matched therapies late in the natural history of a patient’s disease as successful as using ...
In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do initial studies using BRAF V600 to guide vemurafenib and cetuximab in patients with colorectal cancer show? Can genomic profiling updates ...